BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 22571785)

  • 1. Recent advances in positron emission tomography (PET) radiotracers for imaging phosphodiesterases.
    Andrés JI; De Angelis M; Alcázar J; Celen S; Bormans G
    Curr Top Med Chem; 2012; 12(11):1224-36. PubMed ID: 22571785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges on Cyclic Nucleotide Phosphodiesterases Imaging with Positron Emission Tomography: Novel Radioligands and (Pre-)Clinical Insights since 2016.
    Schröder S; Scheunemann M; Wenzel B; Brust P
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33917199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Radioligands for Cyclic Nucleotide Phosphodiesterase Imaging with Positron Emission Tomography: An Update on Developments Since 2012.
    Schröder S; Wenzel B; Deuther-Conrad W; Scheunemann M; Brust P
    Molecules; 2016 May; 21(5):. PubMed ID: 27213312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of phosphodiesterase as cancer therapeutics.
    Peng T; Gong J; Jin Y; Zhou Y; Tong R; Wei X; Bai L; Shi J
    Eur J Med Chem; 2018 Apr; 150():742-756. PubMed ID: 29574203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-Based Discovery of PDEs Inhibitors.
    Li L; Chen W; Chen T; Ren J; Xu Y
    Curr Top Med Chem; 2016; 16(9):917-33. PubMed ID: 26303429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors.
    Castro A; Jerez MJ; Gil C; Martinez A
    Med Res Rev; 2005 Mar; 25(2):229-44. PubMed ID: 15514991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in Cyclic Nucleotide Phosphodiesterase-Targeted PET Imaging and Drug Discovery.
    Sun J; Xiao Z; Haider A; Gebhard C; Xu H; Luo HB; Zhang HT; Josephson L; Wang L; Liang SH
    J Med Chem; 2021 Jun; 64(11):7083-7109. PubMed ID: 34042442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of Compartmentalised Cyclic Nucleotide Signalling via Local Inhibition of Phosphodiesterase Activity.
    Brescia M; Zaccolo M
    Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27706091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of phosphodiesterases in schizophrenia : therapeutic implications.
    Siuciak JA
    CNS Drugs; 2008; 22(12):983-93. PubMed ID: 18998737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for the activity of five adenosine-3',5'-monophosphate-degrading phosphodiesterase isozymes in the adult rat neocortex.
    Sutor B; Mantell K; Bacher B
    Neurosci Lett; 1998 Aug; 252(1):57-60. PubMed ID: 9756358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease.
    Cheng J; Grande JP
    Exp Biol Med (Maywood); 2007 Jan; 232(1):38-51. PubMed ID: 17202584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a series of novel carbon-11 labeled PDE10A inhibitors.
    Stepanov V; Miura S; Takano A; Amini N; Nakao R; Hasui T; Nakashima K; Taniguchi T; Kimura H; Kuroita T; Halldin C
    J Labelled Comp Radiopharm; 2015 May; 58(5):202-8. PubMed ID: 25891816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, in vivo occupancy, and radiolabeling of potent phosphodiesterase subtype-10 inhibitors as candidates for positron emission tomography imaging.
    Andrés JI; De Angelis M; Alcázar J; Iturrino L; Langlois X; Dedeurwaerdere S; Lenaerts I; Vanhoof G; Celen S; Bormans G
    J Med Chem; 2011 Aug; 54(16):5820-35. PubMed ID: 21777010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein-Protein Interactions of Phosphodiesterases.
    Al-Nema MY; Gaurav A
    Curr Top Med Chem; 2019; 19(7):555-564. PubMed ID: 30931862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair.
    Knott EP; Assi M; Rao SN; Ghosh M; Pearse DD
    Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28338622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K
    Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Behaviour of [11C]R(-)- and [11C]S(+)-rolipram in vitro and in vivo, and their use as PET radiotracers for the quantificative assay of PDE4.
    Parker CA; Matthews JC; Gunn RN; Martarello L; Cunningham VJ; Dommett D; Knibb ST; Bender D; Jakobsen S; Brown J; Gee AD
    Synapse; 2005 Mar; 55(4):270-9. PubMed ID: 15668983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors.
    Verghese MW; McConnell RT; Strickland AB; Gooding RC; Stimpson SA; Yarnall DP; Taylor JD; Furdon PJ
    J Pharmacol Exp Ther; 1995 Mar; 272(3):1313-20. PubMed ID: 7891349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second messenger systems as targets for new therapeutic agents: focus on selective phosphodiesterase inhibitors.
    Palacios JM; Beleta J; Segarra V
    Farmaco; 1995 Dec; 50(12):819-27. PubMed ID: 8634072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclic nucleotide phosphodiesterases in heart and vessels: A therapeutic perspective.
    Bobin P; Belacel-Ouari M; Bedioune I; Zhang L; Leroy J; Leblais V; Fischmeister R; Vandecasteele G
    Arch Cardiovasc Dis; 2016; 109(6-7):431-43. PubMed ID: 27184830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.